Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

For patients with symptomatic aortic regurgitation at high surgical risk, a transcatheter aortic valve replacement system ...

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

Transcatheter Aortic Valve Replacement Market outlook through 2035, highlighting key trends, growth drivers, challenges, and future opportunities ...

Anteris Technologies Global Corp.’s AVR share price has surged by 12.25%, which has investors questioning if this is right time to sell.

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

There’s room on the market for new TAVI valves as long as they can compete with the best in practice, a researcher says.

In more serious cases, aortic valve replacement may be the best option. This can be done with traditional, open-heart surgery or with a relatively newer procedure known as transcatheter aortic ...

Tariff talk will continue in the second week of earnings season, but the updates could also shed light on trends and ...